Tech-PN for Pelvic Inflammatory Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to support young women with pelvic inflammatory disease (PID) in Baltimore. It uses community health nurse visits and text messages to help women adhere to their treatment plans and prevent future infections. One group will receive extra support through additional testing and visits, while the other group receives standard care. The trial seeks women with mild to moderate PID who are managing it outside the hospital and live permanently in the Baltimore area. As an unphased trial, it offers participants the chance to contribute to innovative care strategies that could improve treatment adherence and prevent future infections.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What prior data suggests that this protocol is safe for young women with pelvic inflammatory disease?
A previous study found the TECH-PN treatment to be well-tolerated by participants. Research shows that this approach, which includes visits from community health nurses, support through text messages, and extra testing, is safe for young women with pelvic inflammatory disease (PID). Participants reported no serious side effects and found the program easy to follow and helpful. This suggests that TECH-PN is safe and could be a promising way to improve adherence to PID treatment among young women.12345
Why are researchers excited about this trial?
Researchers are excited about Tech-PN for Pelvic Inflammatory Disease because it offers a comprehensive approach by combining community health nurse visits, text-messaging support, and additional testing with field-based visits from a nurse practitioner. Unlike standard care, which typically involves only antibiotics and basic follow-up, Tech-PN introduces a more personalized and supportive care model. This approach aims to improve patient adherence and outcomes by ensuring continuous care and communication, potentially leading to better health results for those affected by the condition.
What evidence suggests that this trial's treatments could be effective for pelvic inflammatory disease?
Research has shown that the TECH-PN program, which participants in this trial may receive, could assist women with pelvic inflammatory disease (PID). Studies have found that similar technology-based community health nursing methods help people adhere to their treatment plans and reduce the risk of recurrent infections. The program also includes a proven plan to prevent sexually transmitted infections (STIs), which should help reduce repeat infections. Early results suggest that TECH-PN is practical and well-received by young women, making it a promising approach to managing PID. While more research is needed, the initial findings are hopeful for better health outcomes and cost savings.12678
Who Is on the Research Team?
Maria Trent, MD, MPH
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for young women aged 13-25 in the Baltimore area who have been diagnosed with mild to moderate pelvic inflammatory disease (PID) and are not pregnant. Participants must be willing to sign informed consent, agree to randomization, and be able to communicate and complete study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive community health nurse visits, text-messaging support, additional testing, and field-based visits with a nurse practitioner
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tech-PN
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute of Nursing Research (NINR)
Collaborator